Affiliation:
1. Département de pharmacie , Unité de Recherche en Pratique Pharmaceutique , Montréal , QC , Canada
2. Faculté de pharmacie , Université de Montréal , Montréal , QC , Canada
Abstract
Abstract
Objectives
The aim of this study was to review studies describing the use and the impact of technology-assisted workflow (TAWF) systems for drug compounding in hospital pharmacy.
Content
This is a scoping literature review. A search was conducted on studies describing or evaluating the use of TAWF published from January 1st, 2015 to July 31st, 2021. Two databases were searched (PubMed and Embase), followed by a search on Google Scholar.
Summary
218 articles were screened and 17 were identified as meeting the inclusion criteria. TAWFs all included preparation assistance software (17/17), barcode reader (17/17), photo or video taking (17/17), and some included gravimetric systems (8/17), and the use of robots (2/17). A majority of the studies included used technology for parenteral preparations (15/17, one for oral preparations only (1/17), and one used technology for both types of preparations (1/17). Most of the articles selected presented drugs prepared for adults (10/17), the others presented drugs intended for children (4/17) or for a mix of adults and children (3/17). Four parameters were evaluated: error detection rate (n=15), preparation and validation time (n=7), and costs generated or saved (n=7). Ten studies evaluated the pre-post impact of implantation of a TAWF (10/17).
Outlook
Given the heterogeneity of the data available, the use of TAWF was associated with an increased ability to detect preparation errors, a reduction in preparation time and costs, and increased satisfaction of pharmacy technicians and pharmacists. However, better quality studies are needed to confirm the positive impacts studied.
Subject
Pharmacology (medical),Pharmacology,Pharmacy
Reference37 articles.
1. Food and Drug Administration. Compounding and the FDA: questions and answers. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.
2. Randell, MD, Duffy, PJ. Risk and liabilities of prescribing compounded medications. Postgrad Med 2014;126:178–80. https://doi.org/10.3810/pgm.2014.07.2816.
3. Gudeman, J, Jozwiakowski, M, Chollet, J, Randell, M. Potential risks of pharmacy compounding. Drugs R D 2013;13:1–8. https://doi.org/10.1007/s40268-013-0005-9.
4. Mullarkey, T. Pharmacy compounding of high-risk level products and patient safety. Am J Health 2009;66:S4–13. https://doi.org/10.2146/ajhp0108b.
5. Watson, CJ, Whitledge, JD, Siani, AM, Burns, MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol 2021;17:197–217. https://doi.org/10.1007/s13181-020-00814-3.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献